Home > News > Universities, Not Companies, Drive Biotech Advancement
May 8th, 2007
Universities, Not Companies, Drive Biotech Advancement
Abstract:
A study by Marks & Clerk, an intellectual property firm based in the United Kingdom, has found that during the period between 2002 and 2006, universities like UCSF and public research institutes, rather than private companies, drove advances in biotechnology.
The results of the study, released at the BIO conference in Boston, were reported in the Monday, May 7, 2007, edition of the Financial Times.
• Among US and Canadian universities, the University of California system is runner-up behind MIT in turning knowledge into commercially viable products and start-up companies.
• UC ranked first for numbers of US biotech patents issued, with 723 patents between 2000 and 2004.
• UC produces the second-highest number of start-up businesses, approximately 20 a year.
• Three UC campuses are in the top 10 rankings worldwide as measured by research publications, US patents issued and the commercial impact of the discoveries. They are UCSF (4th), UC San Diego (6th) and UCLA (10th). Harvard University is No. 1 based on the three performance indicators.
• One out of every five nanotech patents comes from the UC system.
Source:
pub.ucsf.edu
Bookmark:
| Related News Press |
Academic/Education
Rice University launches Rice Synthetic Biology Institute to improve lives January 12th, 2024
Multi-institution, $4.6 million NSF grant to fund nanotechnology training September 9th, 2022
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||